Kala Azar in South Asia
-15%
portes grátis
Kala Azar in South Asia
Current Status and Sustainable Challenges
Jha, T.K.; Noiri, E.
Springer International Publishing AG
01/2017
309
Dura
Inglês
9783319436111
15 a 20 dias
799
Descrição não disponível.
Preface. Part I Introduction into Kala-Azar Pathology and Mechanism of Disease in Kala-Azar.-
Treatment of Post-kala-azar Dermal Leishmaniasis.- Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System.- Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries.- Part II Therapeutic Strategy to Deal with Emergence of Drug Resistance.- A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance.- Treatment of Post-kala-azar Dermal Leishmaniasis.- Combination Therapy for Leishmaniasis.- Vaccine Development for Leishmaniasis.- Siccanin is a novel selective inhibitor of trypanosomatid complex II (succinate-ubiquinone reductase) and a potent broad-spectrum anti-trypanosomatid drug candidate.- Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinent.- Part III Diagnostic Strategy Enhancing Kala-Azar Elimination Program.- Changes of Leishmania antigens in kala-azar patients' urine after treatment.- Potentiality of Urinary L-FABP Tests to Kala-azar Disease Management.- Antibody Capture Direct Agglutination Test (abcDAT) for Diagnosis of Visceral Leishmaniasis with Urine.- Loop-mediated Isothermal Amplification (LAMP): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis.- Applicability of Multiplex Real-Time PCR to Visceral Leishmaniasis.- Immunoglobulins in the Pathophysiology of Visceral Leishmaniasis.- Part V Knowledge and Practice for Vector Control in Kala-Azar.- Geographical Distribution and Ecological Aspect of Sand Fly Species in Bangladesh.- The efficacy of long lasting insecticidal nets for leishmaniasis in Asia.- Environmental change and kala-azar with particular reference to Bangladesh.- Part VI. New Challenges in the Kala-azar Elimination Programme.- Drug Safety Monitoring for Liposomal Amphotericin B.-
Resolution Mapping of Kala-azar Hot Spots Using GPS Logger and Urinary Antibody Measurements.-
Geography and Reality of Kala-azar Endemic in Bangladesh, Analysis Using GIS and Urine-based Mass Screening.- Animal Models of Visceral Leishmaniasis and Applicability to Disease Control.-
Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis. Index.
Treatment of Post-kala-azar Dermal Leishmaniasis.- Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System.- Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries.- Part II Therapeutic Strategy to Deal with Emergence of Drug Resistance.- A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance.- Treatment of Post-kala-azar Dermal Leishmaniasis.- Combination Therapy for Leishmaniasis.- Vaccine Development for Leishmaniasis.- Siccanin is a novel selective inhibitor of trypanosomatid complex II (succinate-ubiquinone reductase) and a potent broad-spectrum anti-trypanosomatid drug candidate.- Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinent.- Part III Diagnostic Strategy Enhancing Kala-Azar Elimination Program.- Changes of Leishmania antigens in kala-azar patients' urine after treatment.- Potentiality of Urinary L-FABP Tests to Kala-azar Disease Management.- Antibody Capture Direct Agglutination Test (abcDAT) for Diagnosis of Visceral Leishmaniasis with Urine.- Loop-mediated Isothermal Amplification (LAMP): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis.- Applicability of Multiplex Real-Time PCR to Visceral Leishmaniasis.- Immunoglobulins in the Pathophysiology of Visceral Leishmaniasis.- Part V Knowledge and Practice for Vector Control in Kala-Azar.- Geographical Distribution and Ecological Aspect of Sand Fly Species in Bangladesh.- The efficacy of long lasting insecticidal nets for leishmaniasis in Asia.- Environmental change and kala-azar with particular reference to Bangladesh.- Part VI. New Challenges in the Kala-azar Elimination Programme.- Drug Safety Monitoring for Liposomal Amphotericin B.-
Resolution Mapping of Kala-azar Hot Spots Using GPS Logger and Urinary Antibody Measurements.-
Geography and Reality of Kala-azar Endemic in Bangladesh, Analysis Using GIS and Urine-based Mass Screening.- Animal Models of Visceral Leishmaniasis and Applicability to Disease Control.-
Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis. Index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Neglected Tropical Diseases;succinate-coenzyme Q reductase;multiplex PCR;urine;Geographic Information System;vector control;antibacterial drug resistance
Preface. Part I Introduction into Kala-Azar Pathology and Mechanism of Disease in Kala-Azar.-
Treatment of Post-kala-azar Dermal Leishmaniasis.- Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System.- Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries.- Part II Therapeutic Strategy to Deal with Emergence of Drug Resistance.- A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance.- Treatment of Post-kala-azar Dermal Leishmaniasis.- Combination Therapy for Leishmaniasis.- Vaccine Development for Leishmaniasis.- Siccanin is a novel selective inhibitor of trypanosomatid complex II (succinate-ubiquinone reductase) and a potent broad-spectrum anti-trypanosomatid drug candidate.- Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinent.- Part III Diagnostic Strategy Enhancing Kala-Azar Elimination Program.- Changes of Leishmania antigens in kala-azar patients' urine after treatment.- Potentiality of Urinary L-FABP Tests to Kala-azar Disease Management.- Antibody Capture Direct Agglutination Test (abcDAT) for Diagnosis of Visceral Leishmaniasis with Urine.- Loop-mediated Isothermal Amplification (LAMP): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis.- Applicability of Multiplex Real-Time PCR to Visceral Leishmaniasis.- Immunoglobulins in the Pathophysiology of Visceral Leishmaniasis.- Part V Knowledge and Practice for Vector Control in Kala-Azar.- Geographical Distribution and Ecological Aspect of Sand Fly Species in Bangladesh.- The efficacy of long lasting insecticidal nets for leishmaniasis in Asia.- Environmental change and kala-azar with particular reference to Bangladesh.- Part VI. New Challenges in the Kala-azar Elimination Programme.- Drug Safety Monitoring for Liposomal Amphotericin B.-
Resolution Mapping of Kala-azar Hot Spots Using GPS Logger and Urinary Antibody Measurements.-
Geography and Reality of Kala-azar Endemic in Bangladesh, Analysis Using GIS and Urine-based Mass Screening.- Animal Models of Visceral Leishmaniasis and Applicability to Disease Control.-
Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis. Index.
Treatment of Post-kala-azar Dermal Leishmaniasis.- Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System.- Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries.- Part II Therapeutic Strategy to Deal with Emergence of Drug Resistance.- A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance.- Treatment of Post-kala-azar Dermal Leishmaniasis.- Combination Therapy for Leishmaniasis.- Vaccine Development for Leishmaniasis.- Siccanin is a novel selective inhibitor of trypanosomatid complex II (succinate-ubiquinone reductase) and a potent broad-spectrum anti-trypanosomatid drug candidate.- Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinent.- Part III Diagnostic Strategy Enhancing Kala-Azar Elimination Program.- Changes of Leishmania antigens in kala-azar patients' urine after treatment.- Potentiality of Urinary L-FABP Tests to Kala-azar Disease Management.- Antibody Capture Direct Agglutination Test (abcDAT) for Diagnosis of Visceral Leishmaniasis with Urine.- Loop-mediated Isothermal Amplification (LAMP): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis.- Applicability of Multiplex Real-Time PCR to Visceral Leishmaniasis.- Immunoglobulins in the Pathophysiology of Visceral Leishmaniasis.- Part V Knowledge and Practice for Vector Control in Kala-Azar.- Geographical Distribution and Ecological Aspect of Sand Fly Species in Bangladesh.- The efficacy of long lasting insecticidal nets for leishmaniasis in Asia.- Environmental change and kala-azar with particular reference to Bangladesh.- Part VI. New Challenges in the Kala-azar Elimination Programme.- Drug Safety Monitoring for Liposomal Amphotericin B.-
Resolution Mapping of Kala-azar Hot Spots Using GPS Logger and Urinary Antibody Measurements.-
Geography and Reality of Kala-azar Endemic in Bangladesh, Analysis Using GIS and Urine-based Mass Screening.- Animal Models of Visceral Leishmaniasis and Applicability to Disease Control.-
Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis. Index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
